Deflexifol is our most advanced drug reformulation and has the potential to improve treatment outcomes for patients with metastatic disease. Fivephusion Pty Ltd aims to develop and commercialise proprietary reformulations of widely prescribed anti-metabolic agents targeting solid tissue cancers. Defelexifol is available for licencing or a commercialisation partnership.
Fusing the cornerstone chemotherapeutic drugs 5-fluorouracil and leucovorin, Deflexifol offers the following benefits in treating colo-rectal cancer (CRC):
• potentially increased efficacy over standard treatments
• simultaneous administration of all therapeutic ingredients
• significantly reduced time of administration
• scalable production
• low cost of manufacturing materials.